Compare Bristol-Myers Squibb Co (BMY) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Invesco Preferred ETF — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Invesco Preferred ETF trades at $10.87. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Invesco Preferred ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| BMY | PGX | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $11.87 |
52-Week Low | $42.60 | $10.82 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
PGX trades at $10.83, down 0.18% with a bearish technical signal from moving averages. Recent news includes the sale of the Golden Sidewalk Project to Kenorland Exploration. Financial ratios are unavailable in the current data, limiting fundamental assessment. The stock faces negative sentiment from recent analyst coverage questioning its risk-reward profile.
The outlook remains cautious given bearish technical indicators and critical analyst commentary highlighting poor returns and limited downside protection. Investment opportunities appear constrained by structural concerns, while risks include participation in market selloffs and recovery rate uncertainties in debt instruments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
